---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-333853"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2026-08-05T11:17:00+00:00"
generated_at: "2026-08-05T11:20:09.438191+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics Q2 net loss $56.6M; initiates RAP-219 Phase 3 in focal seizures

## Summary
- Net loss $56.6M in Q2 2026 vs $26.7M in Q2 2025; R&D spend $51.4M (up from $22.7M).
- Cash $436.1M at June 30, 2026, down from $476.8M at March 31; runway into H2 2029.
- Phase 3 program for RAP-219 in focal onset seizures initiated (FOCUS 1 and FOCUS 2 enrolling).
- Phase 2 bipolar mania trial topline results expected October 2026; RAP-219 half-life now 22 days.
- IND approved in China for RAP-219 Phase 3 trials; RAP-641 IND-enabling activities continue.

## SEC filing metadata
- accession: 0001193125-26-333853
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2026-08-05T11:17:00+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/0001193125-26-333853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312526333853/rapp-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-333853
- JSON: https://secwatch.observer/filing/0001193125-26-333853.json
- Plain text: https://secwatch.observer/filing/0001193125-26-333853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.